Free Trial

Bank of New York Mellon Corp Boosts Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

ANI Pharmaceuticals logo with Medical background
Remove Ads

Bank of New York Mellon Corp grew its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 3.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 123,832 shares of the specialty pharmaceutical company's stock after acquiring an additional 4,404 shares during the quarter. Bank of New York Mellon Corp owned about 0.59% of ANI Pharmaceuticals worth $6,845,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. KBC Group NV increased its stake in shares of ANI Pharmaceuticals by 89.2% in the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock worth $70,000 after acquiring an additional 600 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of ANI Pharmaceuticals by 24.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company's stock worth $177,000 after acquiring an additional 579 shares during the last quarter. HighTower Advisors LLC acquired a new stake in shares of ANI Pharmaceuticals in the 3rd quarter worth $222,000. Hohimer Wealth Management LLC acquired a new stake in shares of ANI Pharmaceuticals in the 3rd quarter worth $264,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of ANI Pharmaceuticals by 10.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company's stock worth $246,000 after acquiring an additional 412 shares during the last quarter. 76.05% of the stock is owned by institutional investors and hedge funds.

Remove Ads

ANI Pharmaceuticals Stock Performance

ANIP traded up $0.13 during trading on Tuesday, hitting $64.48. 9,167 shares of the stock were exchanged, compared to its average volume of 238,643. The firm has a market capitalization of $1.40 billion, a P/E ratio of -117.24 and a beta of 0.63. ANI Pharmaceuticals, Inc. has a 1-year low of $52.50 and a 1-year high of $70.81. The stock has a fifty day moving average price of $58.59 and a two-hundred day moving average price of $58.07. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $60.20, for a total value of $60,200.00. Following the transaction, the senior vice president now directly owns 68,624 shares in the company, valued at approximately $4,131,164.80. This trade represents a 1.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total value of $25,332.00. Following the completion of the sale, the vice president now owns 80,545 shares in the company, valued at approximately $5,100,914.85. This trade represents a 0.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 3,200 shares of company stock valued at $191,776 over the last quarter. Company insiders own 12.70% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on ANIP shares. Guggenheim increased their price target on ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. HC Wainwright reiterated a "buy" rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday. Leerink Partners started coverage on ANI Pharmaceuticals in a report on Wednesday, December 11th. They set an "outperform" rating and a $80.00 price target for the company. Jefferies Financial Group started coverage on ANI Pharmaceuticals in a report on Friday. They set a "buy" rating and a $80.00 price target for the company. Finally, StockNews.com upgraded ANI Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Friday. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $79.75.

Get Our Latest Stock Report on ANI Pharmaceuticals

ANI Pharmaceuticals Company Profile

(Free Report)

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

Featured Articles

Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Should You Invest $1,000 in ANI Pharmaceuticals Right Now?

Before you consider ANI Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANI Pharmaceuticals wasn't on the list.

While ANI Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

NVIDIA’s Dip Is a Gift—Here’s Why It Won’t Last

NVIDIA’s Dip Is a Gift—Here’s Why It Won’t Last

NVIDIA is falling closer to the $100 mark—could it drop even further? Analysts predict up to 50% upside; is this a buying opportunity or a warning sign?

Related Videos

Is There Still Money in AI? How to Invest in the Next Big Wave
3 AI Stocks to Watch After NVIDIA’s Dip
5 Stocks to BUY NOW in March 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads